{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:04:21Z","timestamp":1777100661754,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mass drug administration (MDA) of antifilarial drugs is the main strategy for the elimination of lymphatic filariasis (LF). Recent clinical trials indicated that the triple-drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) is much more effective against LF than the widely used two-drug combinations (albendazole plus either ivermectin or diethylcarbamazine). For IDA-based MDA, the stop-MDA decision is made based on microfilariae (mf) prevalence in adults. In this study, we assess how the probability of eventually reaching elimination of transmission depends on the critical threshold used in transmission assessment surveys (TAS-es) to define whether transmission was successfully suppressed and triple-drug MDA can be stopped. This analysis focuses on treatment-naive Indian settings. We do this for a range of epidemiological and programmatic contexts, using the established LYMFASIM model for transmission and control of LF. Based on our simulations, a single TAS, one year after the last MDA round, provides limited predictive value of having achieved suppressed transmission, while a higher MDA coverage increases elimination probability, thus leading to a higher predictive value. Every additional TAS, conditional on previous TAS-es being passed with the same threshold, further improves the predictive value for low values of stop-MDA thresholds. An mf prevalence threshold of 0.5% corresponding to TAS-3 results in \u226595% predictive value even when the MDA coverage is relatively low.<\/jats:p>","DOI":"10.1093\/cid\/ciae019","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:29:33Z","timestamp":1714062573000},"page":"S131-S137","source":"Crossref","is-referenced-by-count":5,"title":["Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2562-347X","authenticated-orcid":false,"given":"Ananthu","family":"James","sequence":"first","affiliation":[{"name":"Department of Public Health, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc E","family":"Coffeng","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Blok","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D","family":"King","sequence":"additional","affiliation":[{"name":"Department of Control of Neglected Tropical Diseases, World Health Organization , Geneva , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sake J","family":"de Vlas","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilma A","family":"Stolk","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2024042516214436500_ciae019-B1","doi-asserted-by":"crossref","first-page":"e1186","DOI":"10.1016\/S2214-109X(20)30286-2","article-title":"The global distribution of lymphatic filariasis, 2000\u201318: a geospatial analysis","volume":"8","author":"Local Burden of Disease 2019 Neglected Tropical Diseases Collaborators","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2024042516214436500_ciae019-B2","volume-title":"Institute of Medicine (US) Forum on Microbial Threats. The causes and impacts of neglected tropical and zoonotic diseases: opportunities for integrated intervention strategies","author":"Ottesen","year":"2011"},{"key":"2024042516214436500_ciae019-B3","first-page":"489","article-title":"Global Programme to Eliminate Lymphatic Filariasis: progress report 2022","volume":"41","author":"World Health Organization","year":"2023","journal-title":"Wkly Epidemiological Rec"},{"key":"2024042516214436500_ciae019-B4","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A trial of a triple-drug treatment for lymphatic filariasis","volume":"379","author":"King","year":"2018","journal-title":"N Engl J Med"},{"key":"2024042516214436500_ciae019-B5","doi-asserted-by":"crossref","first-page":"e0009069","DOI":"10.1371\/journal.pntd.0009069","article-title":"An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India","volume":"15","author":"Jambulingam","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516214436500_ciae019-B6","doi-asserted-by":"crossref","first-page":"e0009294","DOI":"10.1371\/journal.pntd.0009294","article-title":"An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia","volume":"15","author":"Supali","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516214436500_ciae019-B7","doi-asserted-by":"crossref","first-page":"e0010096","DOI":"10.1371\/journal.pntd.0010096","article-title":"Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: an open-label, cluster-randomised trial","volume":"16","author":"Tavul","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516214436500_ciae019-B8","author":"World Health Organization","year":"2017"},{"key":"2024042516214436500_ciae019-B9","first-page":"29","article-title":"Introduction of triple-drug therapy for accelerating lymphatic filariasis elimination in India: lessons learned","volume":"106","author":"Tripathi","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"2024042516214436500_ciae019-B10","author":"World Health Organization","year":"2013"},{"key":"2024042516214436500_ciae019-B11","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMc1914262","article-title":"Single-dose triple-drug therapy for Wuchereria bancrofti","volume":"382","author":"King","year":"2020","journal-title":"N Engl J Med"},{"key":"2024042516214436500_ciae019-B12","volume-title":"Diagnostic test for surveillance of lymphatic filariasis to support decisions for stopping triple-therapy mass drug administration: target product profile","author":"World Health Organization","year":"2021"},{"key":"2024042516214436500_ciae019-B13","doi-asserted-by":"crossref","first-page":"e0009968","DOI":"10.1371\/journal.pntd.0009968","article-title":"Diagnostics to support elimination of lymphatic filariasis\u2014development of 2 target product profiles","volume":"15","author":"Won","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516214436500_ciae019-B14","doi-asserted-by":"crossref","first-page":"e0006583","DOI":"10.1371\/journal.pntd.0006583","article-title":"Identifying residual transmission of lymphatic filariasis after mass drug administration: comparing school-based versus community-based surveillance\u2014American Samoa, 2016","volume":"12","author":"Sheel","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516214436500_ciae019-B15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/aje\/kwz109","article-title":"Predictive value of Ov16 antibody prevalence in different subpopulations for elimination of African onchocerciasis","volume":"188","author":"Coffeng","year":"2019","journal-title":"Am J Epidemiol"},{"key":"2024042516214436500_ciae019-B16","doi-asserted-by":"crossref","first-page":"e0010953","DOI":"10.1371\/journal.pntd.0010953","article-title":"Comparing antigenaemia and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa","volume":"16","author":"Stolk","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516214436500_ciae019-B17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"Irvine","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2024042516214436500_ciae019-B18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0031182004004822","article-title":"The dynamics of Wuchereria bancrofti infection: a model-based analysis of longitudinal data from Pondicherry, India","volume":"128","author":"Subramanian","year":"2004","journal-title":"Parasitology"},{"key":"2024042516214436500_ciae019-B19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s13071-016-1768-y","article-title":"Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators","volume":"9","author":"Jambulingam","year":"2016","journal-title":"Parasites Vectors"},{"key":"2024042516214436500_ciae019-B20","doi-asserted-by":"crossref","first-page":"e0008033","DOI":"10.1371\/journal.pntd.0008033","article-title":"Modelling for policy: the five principles of the neglected tropical diseases modelling consortium","volume":"14","author":"Behrend","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516214436500_ciae019-B21","doi-asserted-by":"crossref","DOI":"10.1007\/0-306-47661-4_6","volume-title":"The epidemiology of filariasis control","author":"Michael","year":"2002"},{"key":"2024042516214436500_ciae019-B22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1086\/378354","article-title":"Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study","volume":"188","author":"Stolk","year":"2003","journal-title":"J Infect Dis"},{"key":"2024042516214436500_ciae019-B23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/297557a0","article-title":"Population dynamics of human helminth infections: control by chemotherapy","volume":"297","author":"Anderson","year":"1982","journal-title":"Nature"},{"key":"2024042516214436500_ciae019-B24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4269\/ajtmh.21-0768","article-title":"Impact of annual versus semiannual mass drug administration with ivermectin and albendazole on helminth infections in southeastern Liberia","volume":"106","author":"Eneanya","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"2024042516214436500_ciae019-B25","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.1093\/infdis\/jiz647","article-title":"Elimination or resurgence: modelling lymphatic filariasis after reaching the 1% microfilaremia prevalence threshold","volume":"221","author":"Prada","year":"2020","journal-title":"J Infect Dis"},{"key":"2024042516214436500_ciae019-B26","volume-title":"Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures","author":"World Health Organization","year":"2016"},{"key":"2024042516214436500_ciae019-B27","doi-asserted-by":"crossref","first-page":"e0005519","DOI":"10.1371\/journal.pntd.0005519","article-title":"Application of a household-based molecular xenomonitoring strategy to evaluate the lymphatic filariasis elimination program in Tamil Nadu, India","volume":"11","author":"Subramanian","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516214436500_ciae019-B28","author":"National Deworming Day Operational Guidelines"},{"key":"2024042516214436500_ciae019-B29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.4269\/ajtmh.21-0731","article-title":"Impact of semi-annual albendazole on lymphatic filariasis and soil-transmitted helminth infection: parasitological assessment after 14 rounds of community treatment","volume":"106","author":"Pion","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"2024042516214436500_ciae019-B30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(17)30175-5","article-title":"Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo","volume":"17","author":"Pion","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/Supplement_2\/S131\/57334388\/ciae019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/Supplement_2\/S131\/57334388\/ciae019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:29:45Z","timestamp":1714062585000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/Supplement_2\/S131\/7657834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":30,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2024,4,25]]},"published-print":{"date-parts":[[2024,4,25]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae019","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,15]]},"published":{"date-parts":[[2024,4,25]]}}}